FDA Escalates Recall of Compounded Tirzepatide Injections from Apothecary Pharma

Key points

• Apothecary Pharma initiated a voluntary recall of compounded tirzepatide injections on September 24, 2026, citing a lack of assurance of sterility.
• The FDA updated the recall classification to Class II on October 10, 2026, indicating potential temporary or medically reversible adverse health consequences.
• The recall covers 22 specific vials with lot codes ranging from AP-202622 to AP-202644, with beyond-use dates extending through late November 2026.
• In December 2025, the FDA issued a warning letter to Apothecary Pharma for serious deficiencies in sterile production practices.
• Compounded GLP-1 medications are not FDA-approved and are not routinely regulated, raising safety concerns despite their widespread use during drug shortages.

Background

This recall occurs amid ongoing tensions between the FDA and compounding pharmacies regarding GLP-1 medications. Although tirzepatide and semaglutide were removed from the official drug shortage list in late 2024 and early 2025, many compounding pharmacies continued mass production, leading to increased regulatory scrutiny. Previous incidents, such as the 2012 fungal meningitis outbreak linked to unsanitary injections, highlight the risks associated with non-FDA-approved compounded drugs. Recent industry shifts, including Novo Nordisk’s rebranding of GLP-1s as lifestyle products, have further intensified public and regulatory focus on the safety and accessibility of these medications.

Why it matters

The recall underscores the risks associated with compounded medications, which lack the rigorous safety and efficacy evaluations required of FDA-approved drugs. As compounding pharmacies continue to fill gaps in drug supply, patients face potential health risks from sterility issues. This incident may prompt stricter enforcement of FDA regulations on compounding pharmacies and influence patient decisions regarding the source of their GLP-1 medications.

What to watch

Patients with affected lot codes should contact their prescribers for instructions on returning or disposing of the medication. The FDA and Apothecary Pharma have not issued public statements on disposal methods, but online reports suggest prescribers are guiding patients on safe handling. Regulatory actions may follow as the FDA continues to monitor compounding pharmacies for compliance with sterile production standards.